PSTV

Plus Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 4/10
  • Value↓ 0/10
Plus Therapeutics sales and earnings growth
PSTV Growth
Neutral
  • Revenue Y/Y↓ -10.49%
  • EPS Y/Y↑ 85.25%
  • FCF Y/Y↓ -94.50%
Plus Therapeutics gross and profit margin trends
PSTV Profitability
Fair
  • Gross margin ↑ 100.00%
  • EPS margin↓ -429.40%
  • ROIC 5Y↑ 517.96%
Plus Therapeutics net debt vs free cash flow
PSTV Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -5.2

Plus Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks